Logo image of PLRZ

POLYRIZON LTD (PLRZ) Stock Fundamental Analysis

NASDAQ:PLRZ - Nasdaq - IL0011814113 - Common Stock - Currency: USD

0.71  -0.01 (-1.39%)

Fundamental Rating

3

Taking everything into account, PLRZ scores 3 out of 10 in our fundamental rating. PLRZ was compared to 555 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PLRZ as it has an excellent financial health rating, but there are worries on the profitability. PLRZ has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PLRZ had negative earnings in the past year.
In the past year PLRZ has reported a negative cash flow from operations.
PLRZ Yearly Net Income VS EBIT VS OCF VS FCFPLRZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -500K -1M -1.5M

1.2 Ratios

PLRZ has a Return On Assets of -40.18%. This is comparable to the rest of the industry: PLRZ outperforms 56.58% of its industry peers.
Looking at the Return On Equity, with a value of -42.17%, PLRZ is in the better half of the industry, outperforming 69.19% of the companies in the same industry.
Industry RankSector Rank
ROA -40.18%
ROE -42.17%
ROIC N/A
ROA(3y)-99.78%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLRZ Yearly ROA, ROE, ROICPLRZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 5K 10K 15K 20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PLRZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLRZ Yearly Profit, Operating, Gross MarginsPLRZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, PLRZ has about the same amount of shares outstanding.
PLRZ has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLRZ Yearly Shares OutstandingPLRZ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5K 10K 15K
PLRZ Yearly Total Debt VS Total AssetsPLRZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

PLRZ has an Altman-Z score of 2525.47. This indicates that PLRZ is financially healthy and has little risk of bankruptcy at the moment.
PLRZ has a Altman-Z score of 2525.47. This is amongst the best in the industry. PLRZ outperforms 100.00% of its industry peers.
There is no outstanding debt for PLRZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2525.47
ROIC/WACCN/A
WACCN/A
PLRZ Yearly LT Debt VS Equity VS FCFPLRZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 2M 4M

2.3 Liquidity

A Current Ratio of 10.16 indicates that PLRZ has no problem at all paying its short term obligations.
PLRZ has a better Current ratio (10.16) than 78.74% of its industry peers.
A Quick Ratio of 10.16 indicates that PLRZ has no problem at all paying its short term obligations.
The Quick ratio of PLRZ (10.16) is better than 78.74% of its industry peers.
Industry RankSector Rank
Current Ratio 10.16
Quick Ratio 10.16
PLRZ Yearly Current Assets VS Current LiabilitesPLRZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PLRZ have decreased strongly by -329.32% in the last year.
EPS 1Y (TTM)-329.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-236.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PLRZ. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLRZ Price Earnings VS Forward Price EarningsPLRZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLRZ Per share dataPLRZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PLRZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POLYRIZON LTD

NASDAQ:PLRZ (7/2/2025, 10:42:26 AM)

0.71

-0.01 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap1.08B
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 203.95
P/tB 448.82
EV/EBITDA N/A
EPS(TTM)-171.38
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.18%
ROE -42.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-99.78%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.16
Quick Ratio 10.16
Altman-Z 2525.47
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-329.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-236.53%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-113.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-113.59%
OCF growth 3YN/A
OCF growth 5YN/A